BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160+1.95%BGNE0.00%
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC-1.03%06160+1.95%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM06160+1.95%688235+2.06%
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)Tip Ranks·Jul 7 at 12:15 AMONC-1.03%BGNE0.00%
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma | ONC Stock NewsStockTitan·Jun 29 at 09:00 PMONC-1.03%BGNE0.00%
BeOne Medicines Chief Executive Officer Sold Shares Worth Over $933KTradingView·Jun 25 at 04:20 PM688235+2.06%ONC-1.03%
BeOne Medicines Executives Quietly Cash In on a Wave of Insider Stock SalesTip Ranks·Jun 18 at 09:06 PMONC-1.03%688235+2.06%
BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive PlansTip Ranks·Jun 11 at 06:05 PM06160+1.95%688235+2.06%
BeOne Medicines Sets Out Board and Committee Structure to Bolster GovernanceTip Ranks·Jun 11 at 06:04 PMBGNE0.00%06160+1.95%
